81 related articles for article (PubMed ID: 22954029)
1. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
[TBL] [Abstract][Full Text] [Related]
2. Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Lin Y; DiPaola RS; Yao SL
Eur Urol; 2015 Nov; 68(5):805-11. PubMed ID: 25800944
[TBL] [Abstract][Full Text] [Related]
3. Comorbidity and mortality results from a randomized prostate cancer screening trial.
Crawford ED; Grubb R; Black A; Andriole GL; Chen MH; Izmirlian G; Berg CD; D'Amico AV
J Clin Oncol; 2011 Feb; 29(4):355-61. PubMed ID: 21041707
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
de Vos II; Remmers S; Hogenhout R; Roobol MJ;
Eur Urol; 2024 Jan; 85(1):74-81. PubMed ID: 37919190
[TBL] [Abstract][Full Text] [Related]
5. Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis.
Mahal BA; Kwak L; Xie W; Eastham JA; James ND; Sandler HM; Feng FY; Brihoum M; Fizazi K; Sweeney C; Ravi P; D'Amico AV
JAMA Netw Open; 2023 Nov; 6(11):e2340787. PubMed ID: 37910103
[TBL] [Abstract][Full Text] [Related]
6. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
Nguyen PL; Huang HR; Spratt DE; Davicioni E; Sandler HM; Shipley WU; Efstathiou JA; Simko JP; Pollack A; Dicker AP; Roach M; Rosenthal SA; Zeitzer KL; Mendez LC; Hartford AC; Hall WA; Desai AB; Rabinovitch RA; Peters CA; Rodgers JP; Tran P; Feng FY
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):521-529. PubMed ID: 36596347
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study.
Egevad L; Micoli C; Delahunt B; Samaratunga H; Orrason AW; Garmo H; Stattin P; Eklund M
Virchows Arch; 2024 Apr; ():. PubMed ID: 38683251
[TBL] [Abstract][Full Text] [Related]
8. Frequency of Biopsy and Tumor Grade Before vs After Introduction of Prostate Magnetic Resonance Imaging.
Robinson D; Abdulkareem R; Nasrollah D; Ljung A; Hintze P; Wallby S; Ståhlbrandt H; Frennvall T; Styrke J; Stattin P; Garmo H
JAMA Netw Open; 2023 Aug; 6(8):e2330233. PubMed ID: 37606924
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of Gleason Score 9-10 Prostatic Adenocarcinoma in Needle Biopsies: A Nationwide Population-based Study.
Egevad L; Micoli C; Samaratunga H; Delahunt B; Garmo H; Stattin P; Eklund M
Eur Urol Oncol; 2024 Apr; 7(2):213-221. PubMed ID: 37978024
[TBL] [Abstract][Full Text] [Related]
10. Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram.
Kutikov A; Cooperberg MR; Paciorek AT; Uzzo RG; Carroll PR; Boorjian SA
Prostate Cancer Prostatic Dis; 2012 Dec; 15(4):374-9. PubMed ID: 22710832
[TBL] [Abstract][Full Text] [Related]
11. Age dependence of modern clinical risk groups for localized prostate cancer-A population-based study.
Huynh-Le MP; Myklebust TÅ; Feng CH; Karunamuni R; Johannesen TB; Dale AM; Andreassen OA; Seibert TM
Cancer; 2020 Apr; 126(8):1691-1699. PubMed ID: 31899813
[TBL] [Abstract][Full Text] [Related]
12. Racial Disparity in Prostate Cancer-Specific Mortality for High-Risk Prostate Cancer: A Population-Based Study.
Wang C; Kamrava M; King C; Steinberg ML
Cureus; 2017 Jan; 9(1):e961. PubMed ID: 28168138
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis.
Cui F; Tang X; Man C; Fan Y
BMC Cancer; 2024 May; 24(1):628. PubMed ID: 38783246
[TBL] [Abstract][Full Text] [Related]
14. Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort.
Tinsley SA; Finati M; Stephens A; Chiarelli G; Cirulli GO; Williams E; Morrison C; Richard C; Hares K; Sood A; Buffi N; Lughezzani G; Bettocchi C; Salonia A; Briganti A; Montorsi F; Carrieri G; Rogers C; Abdollah F
Cancer; 2024 May; ():. PubMed ID: 38804713
[TBL] [Abstract][Full Text] [Related]
15. Predicting prostate cancer progression: protocol for a retrospective cohort study to identify prognostic factors for prostate cancer outcomes using routine primary care data.
Merriel SWD; May MT; Martin RM
BMJ Open; 2018 Jan; 8(1):e019409. PubMed ID: 29391368
[TBL] [Abstract][Full Text] [Related]
16. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
Cuzick J; Stone S; Fisher G; Yang ZH; North BV; Berney DM; Beltran L; Greenberg D; Møller H; Reid JE; Gutin A; Lanchbury JS; Brawer M; Scardino P
Br J Cancer; 2015 Jul; 113(3):382-9. PubMed ID: 26103570
[TBL] [Abstract][Full Text] [Related]
17. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
Platz EA; Till C; Goodman PJ; Parnes HL; Figg WD; Albanes D; Neuhouser ML; Klein EA; Thompson IM; Kristal AR
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2807-13. PubMed ID: 19887582
[TBL] [Abstract][Full Text] [Related]
18. Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.
Troeschel AN; Hartman TJ; Jacobs EJ; Stevens VL; Gansler T; Flanders WD; McCullough LE; Wang Y
J Clin Oncol; 2020 Jun; 38(18):2018-2027. PubMed ID: 32250715
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Prostate Cancer Screening Strategies in a Low-Resource, High-risk Population in the Bahamas.
Heijnsdijk EAM; Gulati R; Lange JM; Tsodikov A; Roberts R; Etzioni R
JAMA Health Forum; 2022 May; 3(5):e221116. PubMed ID: 35977253
[TBL] [Abstract][Full Text] [Related]
20. Presenting stage and risk group in men dying of prostate cancer.
Parimi S; Bondy S; Aparicio M; Sunderland K; Cho J; Bachand F; Nguyen Chi K; Pickles T; Tyldesley S
Curr Oncol; 2020 Dec; 27(6):e547-e551. PubMed ID: 33380869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
